Loading...
机构名称:
¥ 1.0

• Prescribed by a Neurology or Genetics provider • Patient has a definitive diagnosis of Duchene muscular dystrophy (DMD) based on documented clinical findings and prior genetic testing • Patient is a male • Patient is age 4 years old or older • Patient is ambulatory and able to complete the 10-meter walk test without assistance devices • Patient has anti-AAVrh74 total binding antibody titers <1:400 • Patient does not在DMD基因中的外显子8和/或外显子9中有任何缺失•患者没有接受外显子的疗法,或者必须在开始时至少停止至少1周,•患者未使用其他DMD基因疗法•患者以前没有使用过leveriDys。尚未研究重复给药,不建议•凯撒永久咨询医师小组对患者进行了审查,并建议使用药物

SGLT2抑制剂,SGLT2抑制剂组合的事先授权(PA)形式(二甲双胍,DPP-4delandistrogene moxeparvovec(levidys)

SGLT2抑制剂,SGLT2抑制剂组合的事先授权(PA)形式(二甲双胍,DPP-4delandistrogene moxeparvovec(levidys)PDF文件第1页

相关文件推荐